Nanocrystalline Pharmaceutical Patent Litigation: The First Case

-
Nanotechnology promises to have a major impact on health care. Indeed, one of the first major product success stories to come out of this emerging field is a nanoparticle-based drug for cancer therapy. Abraxane, manufactured by Abraxis, uses albumin nanoparticles to enhance the effectiveness and reduce the side effects of paclitaxel, a chemotherapy drug used for treating breast cancer. In July 2006, Elan Pharmaceuticals filed a complaint alleging that the Abraxane infringes two of Elan's patents regarding nanoparticle formulation technology. After two years of discovery battles, the dispute has finally gone before a jury, which rendered a verdict in favor of Elan for $55.2 million. In this article, IP lawyers William Prendergast and Heather Schafer provide a background of the dispute, summarize the case, and draw conclusions regarding its implications for nanotechnology patent litigation. Source

Comments

Post a Comment

Popular posts from this blog

KMX Pharma Production Explorer

-
All pharmaceutical companies have to operate in accordance with FDA regulations. Recently the FDA has issued guidelines that determine quality control standards for the pharmaceutical production process. For these companies this implies that they will have to measure every important parameter within their production process in order to control and optimize it. Oracle technology in combination with KMX provided a valuable insight in the production process. By applying data mining, generating all possible models from the data and analyzing all relationships between the models. Further optimization of the thus generated models provided not only better quality control of the production process, as required by the FDA, but also greatly improved production planning and saved production costs.
Read more

Building the Business Case for Innovation

-
Innovation has transitioned from a “nice to have” to a top priority for most companies because innovation drives organic growth. Like other business processes, innovation can be managed to achieve results. Unlike other business processes, innovation requires introducing risk, embracing failure, and doing things that are counter to most efficiency driving processes. Building a business case for innovation requires addressing these and other differences based on how innovation will be implemented within the organization. Specifying the approach, the impact on everyone in the organization, and the means by which innovation will occur in an organization drives the business case and increases the likelihood of success.... more
Read more

The influence of drug-like concepts on decision-making in medicinal chemistry

-
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity — the most important drug-like physical property — include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making. Link to article
Read more